Redeye: Remedy - Increasing Valuation Reflecting Strong Year Ahead

Redeye upgrades Remedy’s 2020-21 earnings estimates substantially following the full-year 2019 report, our key take away from which was the company’s positive outlook statement. Indeed, we expect Control (which we believe has had a head start to the year) to drive higher revenues and earnings in 2020, one of several catalysts with potential to take the stock higher still.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.